Olli Yli‐Harja

7.9k total citations · 2 hit papers
230 papers, 4.9k citations indexed

About

Olli Yli‐Harja is a scholar working on Molecular Biology, Genetics and Biophysics. According to data from OpenAlex, Olli Yli‐Harja has authored 230 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 151 papers in Molecular Biology, 31 papers in Genetics and 28 papers in Biophysics. Recurrent topics in Olli Yli‐Harja's work include Gene Regulatory Network Analysis (56 papers), Gene expression and cancer classification (40 papers) and Bioinformatics and Genomic Networks (39 papers). Olli Yli‐Harja is often cited by papers focused on Gene Regulatory Network Analysis (56 papers), Gene expression and cancer classification (40 papers) and Bioinformatics and Genomic Networks (39 papers). Olli Yli‐Harja collaborates with scholars based in Finland, United States and China. Olli Yli‐Harja's co-authors include Ilya Shmulevich, Meenakshisundaram Kandhavelu, Harri Lähdesmäki, Frank Emmert‐Streib, Jaakko Astola, Jyrki Selinummi, André S. Ribeiro, Pekka Ruusuvuori, Matthias Dehmer and Y. Neuvo and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Physical Review Letters and Nucleic Acids Research.

In The Last Decade

Olli Yli‐Harja

218 papers receiving 4.5k citations

Hit Papers

Programmed cell death detection methods: a systematic rev... 2022 2026 2023 2024 2022 2024 50 100 150 200

Peers

Olli Yli‐Harja
Xiaobo Zhou United States
Kun Huang United States
Guido Sanguinetti United Kingdom
Markus W. Covert United States
Sungroh Yoon South Korea
Yu Li China
Xiaobo Zhou United States
Olli Yli‐Harja
Citations per year, relative to Olli Yli‐Harja Olli Yli‐Harja (= 1×) peers Xiaobo Zhou

Countries citing papers authored by Olli Yli‐Harja

Since Specialization
Citations

This map shows the geographic impact of Olli Yli‐Harja's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olli Yli‐Harja with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olli Yli‐Harja more than expected).

Fields of papers citing papers by Olli Yli‐Harja

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olli Yli‐Harja. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olli Yli‐Harja. The network helps show where Olli Yli‐Harja may publish in the future.

Co-authorship network of co-authors of Olli Yli‐Harja

This figure shows the co-authorship network connecting the top 25 collaborators of Olli Yli‐Harja. A scholar is included among the top collaborators of Olli Yli‐Harja based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olli Yli‐Harja. Olli Yli‐Harja is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Saravanan, Konda Mani, Thiyagarajan Ramesh, Olli Yli‐Harja, Meenakshisundaram Kandhavelu, & Akshaya Murugesan. (2023). Structural analysis of human G‐protein‐coupled receptor 17 ligand binding sites. Journal of Cellular Biochemistry. 124(4). 533–544. 1 indexed citations
2.
Mutharasu, Gnanavel, et al.. (2023). Signaling landscape of mitochondrial non-coding RNAs. Journal of Biomolecular Structure and Dynamics. 41(21). 12016–12025. 2 indexed citations
3.
Murugesan, Akshaya, et al.. (2022). P2Y1 agonist HIC in combination with androgen receptor inhibitor abiraterone acetate impairs cell growth of prostate cancer. APOPTOSIS. 27(3-4). 283–295. 3 indexed citations
4.
Yli‐Harja, Olli, et al.. (2021). Molecular interaction study of novel indoline derivatives with EGFR-kinase domain using multiple computational analysis. Journal of Biomolecular Structure and Dynamics. 40(16). 7545–7554. 8 indexed citations
5.
Murugesan, Akshaya, et al.. (2021). Molecular modeling and dynamics studies of the synthetic small molecule agonists with GPR17 and P2Y1 receptor. Journal of Biomolecular Structure and Dynamics. 40(23). 12908–12916. 3 indexed citations
6.
Mutharasu, Gnanavel, Akshaya Murugesan, Konda Mani Saravanan, Olli Yli‐Harja, & Meenakshisundaram Kandhavelu. (2021). Identifying the miRNA Signature Association with Aging-Related Senescence in Glioblastoma. International Journal of Molecular Sciences. 22(2). 517–517. 9 indexed citations
7.
Doan, Phuong L., Akshaya Murugesan, Kumar Subramanian, et al.. (2021). Targeting Orphan G Protein-Coupled Receptor 17 with T0 Ligand Impairs Glioblastoma Growth. Cancers. 13(15). 3773–3773. 8 indexed citations
8.
Murugesan, Akshaya, Ana S. Macedo, Nga T. T. Nguyen, et al.. (2020). Design and Synthesis of Novel Quinic Acid Derivatives: In Vitro Cytotoxicity and Anticancer Effect on Glioblastoma. Future Medicinal Chemistry. 12(21). 1891–1910. 14 indexed citations
9.
Murugesan, Akshaya, et al.. (2020). Anticancer activity of THMPP: Downregulation of PI3K/ S6K1 in breast cancer cell line. Saudi Pharmaceutical Journal. 28(4). 495–503. 5 indexed citations
10.
Yli‐Harja, Olli, et al.. (2020). Alkylamino Phenol Derivative Induces Apoptosis by Inhibiting EGFR Signaling Pathway in Breast Cancer Cells. Anti-Cancer Agents in Medicinal Chemistry. 20(7). 809–819. 6 indexed citations
11.
Musa, Aliyu, Konda Mani Saravanan, Frank Emmert‐Streib, et al.. (2019). 2-(2-(2,4-dioxopentan-3-ylidene)hydrazineyl)benzonitrile as novel inhibitor of receptor tyrosine kinase and PI3K/AKT/mTOR signaling pathway in glioblastoma. European Journal of Medicinal Chemistry. 166. 291–303. 49 indexed citations
12.
Saravanan, Konda Mani, et al.. (2019). Synthesis and preclinical validation of novel P2Y1 receptor ligands as a potent anti-prostate cancer agent. Scientific Reports. 9(1). 18938–18938. 21 indexed citations
13.
Doan, Phuong L., Vinoth Kumar Megraj Khandelwal, Федор И. Зубков, et al.. (2018). In vitro characterization of arylhydrazones of active methylene derivatives. Saudi Pharmaceutical Journal. 26(3). 430–436. 4 indexed citations
14.
Marucci, Gabriella, Michela Buccioni, Catia Lambertucci, et al.. (2018). Anticancer activity study of A 3 adenosine receptor agonists. Life Sciences. 205. 155–163. 13 indexed citations
15.
Doan, Phuong L., et al.. (2017). Effect of alkylaminophenols on growth inhibition and apoptosis of bone cancer cells. European Journal of Pharmaceutical Sciences. 107. 208–216. 24 indexed citations
16.
Ylipää, Antti, Kati Kivinummi, Matti Annala, et al.. (2015). Transcriptome Sequencing Reveals PCAT5 as a Novel ERG-Regulated Long Noncoding RNA in Prostate Cancer. Cancer Research. 75(19). 4026–4031. 58 indexed citations
17.
Oliveira, Samuel M. D., et al.. (2015). Single-cell kinetics of a repressilator when implemented in a single-copy plasmid. Molecular BioSystems. 11(7). 1939–1945. 2 indexed citations
18.
Mutharasu, Gnanavel, Olli Yli‐Harja, & Meenakshisundaram Kandhavelu. (2014). PROTEIN-PROTEIN INTERACTION AND COARSE GRAINED SIMULATION STUDY OF GLIOBLASTOMA MULTIFORME REVEALS NOVEL PATHWAYS OF GPR17. SHILAP Revista de lepidopterología. 2 indexed citations
19.
Lloyd‐Price, Jason, et al.. (2011). Probabilistic RNA partitioning generates transient increases in the normalized variance of RNA numbers in synchronized populations of Escherichia coli. Molecular BioSystems. 8(2). 565–571. 16 indexed citations
20.
Charlebois, Daniel A., André S. Ribeiro, Antti Lehmussola, et al.. (2007). Effects of microarray noise on inference efficiency of a stochastic model of gene networks. 4(2). 15–21. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026